All In Biotech

Drug Trial Radar · NCT02497898

Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma

A Randomized Controlled Clinical Trial of Cytokine-induced Killer (CIK) Cells Treatment in Patients With Refractory Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Jul 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jul 2015

Primary completion

Jul 2038

Study completion Jul 2040

Sponsor

Lead sponsor
The First People's Hospital of ChangzhouAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

  • Cytokine-induced killer cells (CIK)Biological

    Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free-Survival (PFS)Time frame: 1 month

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.